Enlivex Reports 79% Response Rate With Allocetra In Older Knee OA Patients
Enlivex (ENLV) reported 12-month Phase IIa trial results showing 79.2% of older knee OA patients receiving Allocetra saw pain reduction and function improvement, vs. 47.6% on placebo. The trial had 134 patients, with no serious adverse events. ENLV plans to present findings at ACR Convergence 2026 and expects Phase IIb results by Q2 2027. ENLV stock is down 15.38% at $1.54.
How this was made
The 30-second read
Why it matters
The data provides a catalyst for ENLV, likely prompting short‑term buying interest and a price uptick.
Market read
First‑report clinical trial results for a small‑cap biotech, offering a clear trading trigger.
What to watch
Potential competition from other OA therapies and the need for larger, longer trials could temper upside.
Background
Enlivex Therapeutics (ENLV) is a biotech focused on age‑related inflammatory conditions. The Phase IIa trial of its cell‑therapy Allocetra in knee osteoarthritis showed statistically significant pain reduction and functional improvement.
Ticker impact
Enlivex Therapeutics reported Phase IIa topline data showing a 79.2% response rate in older knee OA patients, a new primary disclosure.
upward pressure as investors price in the strong efficacy signal.
The trial met its primary endpoint with statistical significance and no serious safety issues, providing material clinical progress for a biotech.
Market effects
Positive OA data may boost sentiment for the broader biotech and musculoskeletal therapeutic sector.
Limited to markets where ENLV trades; no broader regional effect.
Modest, as the result pertains to a niche therapeutic area.
Counterpoint
Skeptics may question the durability of the response and await Phase IIb data before committing.
Key entities
- companyEnlivex Therapeutics Ltd.
Biotech developer of Allocetra.
- productAllocetra
Cell‑based therapy evaluated for knee osteoarthritis.
